Six studies, involving a total of 1171 individuals, were included in the final analysis and each investigated gene was reported in two studies. The studies were published between 2000 and 2014, and 26–420 participants were included in each study. Two of the included studies were carried out in Germany 22,26, one in France 23, one in Italy 19, one in the USA 24, and one in the Czech Republic 25. The mean age of the patients included ranged from 42.7 to 75.3 years, and the percentage of male participants ranged from 21.9 to 84.6%. Study quality was assessed using the Newcastle–Ottawa Scale. We observed that one study scored 8 22, three studies scored 7 23,24,26, and two studies scored 6 19,25.
Our current study was based on available published studies and it explored all possible correlations between SLCO1B1, ApoE, and CYP2C9 polymorphisms and the outcomes of the TC, TG, LDL, and HDL levels. This quantitative study included 1171 individuals from 6 studies distributed across a broad range of baseline characteristics. The results of this study indicated that patient carrier SLCO1B1 521TT significantly affected the percentage change in TC and LDL levels, and that ApoE*2/*3 correlated significantly with changes in HDL levels compared with their corresponding control groups. No significant associations between the CYP2C9 genotypes and TC, TG, and LDL levels were observed. These results added to the accumulating evidence on fluvastatin’s lipid-lowering efficacy with respect to the patient carrier SLCO1B1, ApoE, and CYP2C9 polymorphisms.
Differences in lipid profiles were observed in patient carriers, specifically with respect to the genotypes, from our analysis and the results of previous studies 19,22–26. Meyer zu Schwabedissen et al. 22 carried out a cohort study that evaluated the influence of SLCO1B1 on the therapeutic efficacy of statins in 214 dyslipidemia patients during the 5-year follow-up. They pointed out that patient carrier 521TT induced a small change in LDL levels, without showing any other significant effects. Furthermore, Couvert et al. 23 observed that 521TT correlated with TC levels 2 months after follow-up in elderly hypercholesterolemic patients who received fluvastatin treatments.
This study was supported by grants from the National Key Technologies R&D Program (no. 2016YFC0904900), the National Natural Science Foundation of China (no. 81573504 and no. 81673509), the Beijing Natural Science Foundation (no. 7171012), and the National Science and Technology Major Projects for ‘Major New Drugs Innovation and Development’ (no. 2017ZX09304028 and no. 2017ZX09101001).
There are no conflicts of interest.
1. Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D’Agostino RB, Gibbons R, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129 (Suppl 2):S49–S73.
2. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016; 37:2315–2381.
3. Excellence NIfHaC. Cardiovascular disease: risk assessment and reduction, including lipid modification. London: National Institute for Health and Care Excellence; 2014.
4. Fulcher J, O’Connell R, Voysey M, Emberson J, Blackwell L, Mihaylova B, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis
of individual data from 174,000 participants in 27 randomised trials. Lancet 2015; 385:1397–1405.
5. Jun M, Foote C, Lv J, Neal B, Patel A, Nicholls SJ, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis
. Lancet 2010; 375:1875–1884.
6. Steinberg D. Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem 1997; 272:20963–20966.
7. Steinberg D. At last, direct evidence that lipoxygenases play a role in atherogenesis. J Clin Invest 1999; 103:1487–1488.
8. Brunner EJ, Rees K, Ward K, Burke M, Thorogood M. Dietary advice for reducing cardiovascular risk. Cochrane Database Syst Rev 2007. CD002128.
9. Pasanen MK, Miettinen TA, Gylling H, Neuvonen PJ, Niemi M. Polymorphism of the hepatic influx transporter organic anion transporting polypeptide 1B1 is associated with increased cholesterol synthesis rate. Pharmacogenet Genomics 2008; 18:921–926.
10. Christidis DS, Liberopoulos EN, Kakafika AI, Miltiadous GA, Liamis GL, Kakaidi B, et al. Effect of paraoxonase 1 polymorphisms
on the response of lipids and lipoprotein-associated enzymes to treatment with fluvastatin
. Arch Med Res 2007; 38:403–410.
11. Donnelly LA, Palmer CN, Whitley AL, Lang CC, Doney AS, Morris AD, et al. Apolipoprotein E
genotypes are associated with lipid-lowering responses to statin treatment in diabetes: a Go-DARTS study. Pharmacogenet Genomics 2008; 18:279–287.
12. Niemi M. Role of OATP transporters in the disposition of drugs. Pharmacogenomics 2007; 8:787–802.
13. Niemi M, Pasanen MK, Neuvonen PJ. SLCO1B1
polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin
. Clin Pharmacol Ther 2006; 80:356–366.
14. Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M. SLCO1B1
polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics 2006; 16:873–879.
15. Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi M. Different effects of SLCO1B1
polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 2007; 82:726–733.
16. Hedman M, Antikainen M, Holmberg C, Neuvonen M, Eichelbaum M, Kivistö KT, et al. Pharmacokinetics and response to pravastatin in paediatric patients with familial hypercholesterolaemia and in paediatric cardiac transplant recipients in relation to polymorphisms
of the SLCO1B1
and ABCB1 genes. Br J Clin Pharmacol 2006; 61:706–715.
17. Niemi M, Neuvonen PJ, Hofmann U, Backman JT, Schwab M, Lütjohann D, et al. Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1
(encoding OATP1B1) haplotype *17. Pharmacogenet Genomics 2005; 15:303–309.
18. Tavintharan S, Lim SC, Chan YH, Sum CF. Apolipoprotein E
genotype affects the response to lipid-lowering therapy in Chinese patients with type 2 diabetes mellitus. Diabetes Obes Metab 2007; 9:81–86.
19. Zuccaro P, Mombelli G, Calabresi L, Baldassarre D, Palmi I, Sirtori CR. Tolerability of statins is not linked to CYP450 polymorphisms
, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin
. Pharmacol Res 2007; 55:310–317.
20. Saxena R, Voight BF, Lyssenko V, Burtt NP, de Bakker PI, Chen H, et al. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 2007; 316:1331–1336.
21. Scripture CD, Pieper JA. Clinical pharmacokinetics of fluvastatin
. Clin Pharmacokinet 2001; 40:263–281.
22. Meyer zu Schwabedissen HE, Albers M, Baumeister SE, Rimmbach C, Nauck M, Wallaschofski H, et al. Function-impairing polymorphisms
of the hepatic uptake transporter SLCO1B1
modify the therapeutic efficacy of statins in a population-based cohort. Pharmacogenet Genomics 2015; 25:8–18.
23. Couvert P, Giral P, Dejager S, Gu J, Huby T, Chapman MJ, et al. Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to fluvastatin
therapy. Pharmacogenomics 2008; 9:1217–1227.
24. Ballantyne CM, Herd JA, Stein EA, Ferlic LL, Dunn JK, Gotto AM Jr, et al. Apolipoprotein E
genotypes and response of plasma lipids and progression-regression of coronary atherosclerosis to lipid-lowering drug therapy. J Am Coll Cardiol 2000; 36:1572–1578.
25. Buzkova H, Pechandova K, Danzig V, Vareka T, Perlik F, Zak A, et al. Lipid-lowering effect of fluvastatin
in relation to cytochrome P450 2C9 variant alleles frequently distributed in the Czech population. Med Sci Monit 2012; 188:Cr512–Cr517.
26. Kirchheiner J, Kudlicz D, Meisel C, Bauer S, Meineke I, Roots I, et al. Influence of CYP2C9 polymorphisms
on the pharmacokinetics and cholesterol-lowering activity of (−)-3S,5R-fluvastatin
in healthy volunteers. Clin Pharmacol Ther 2003; 74:186–194.
27. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6:e1000097.
28. Wells G, Shea B, OC D. The Newcastle–Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa (ON): Ottawa Hospital Research Institute.
29. DerSimonian R, Laird N. Meta-analysis
in clinical trials. Control Clin Trials 1986; 7:177–188.
30. Ades AE, Lu G, Higgins JP. The interpretation of random-effects meta-analysis
in decision models. Med Decis Making 2005; 25:646–654.
31. Kopplow K, Letschert K, Konig J, Walter B, Keppler D. Human hepatobiliary transport of organic anions analyzed by quadruple-transfected cells. Mol Pharmacol 2005; 68:1031–1038.
32. Noe J, Portmann R, Brun ME, Funk C. Substrate-dependent drug–drug interactions between gemfibrozil, fluvastatin
and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3. Drug Metab Dispos 2007; 35:1308–1314.